Want to see GB:VAL full AI Analyst Report?
VAL Stock Chart & Stats
0.16 p
<0.01 p(1.56%)
At close: 4:00 PM EDT
0.16 p
<0.01 p(1.56%)
Day’s Range― - ―
52-Week Range0.12 p - 0.53 p
Previous CloseN/A
Volume993.58K
Average Volume (3M)19.45M
Market Cap
£1.85M
Enterprise Value-114.83K
Total Cash (Recent Filing)£970.56K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Jun 09, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,320,301,000
10 Day Avg. Volume50,720,133
30 Day Avg. Volume19,450,104
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.49
Price to Sales (P/S)44.16
P/FCF Ratio-0.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal LeverageMinimal debt reduces interest and refinancing exposure and preserves financial flexibility relative to a highly leveraged biotech. Although the company remains cash-burning, its capital structure does not currently add a significant fixed repayment burden or compound operating weakness.
Focused Therapeutic PipelineA defined focus on oncology and women’s health gives the company a clear scientific direction rather than an unfocused portfolio. Progressing selected preclinical and clinical-stage candidates provides potential development pathways that can support longer-term value creation if assets advance.
Partner-oriented Development ModelA collaboration-based development model can help an early-stage biotech pursue therapeutic candidates without relying solely on internal execution across every development stage. Partner involvement may provide development expertise and commercial pathways as selected assets mature.
Bears Say
Declining, Very Small RevenueRevenue remains too small to support the current operating base and declined materially year over year. This indicates that commercial scale has not yet been established, leaving the company dependent on future asset progress rather than recurring operating revenue over the next several quarters.
Persistent Operating And Net LossesPersistent operating and net losses show that the business remains in a heavy investment phase without a demonstrated path to break-even in the reported results. Continued losses can erode financial resources and make future development dependent on additional funding or successful asset advancement.
Structural Cash Burn And Weakening AssetsNegative operating and free cash flow indicate that operations are not self-funding and that ongoing development requires external financial support. The concurrent reduction in equity and total assets shows that losses are weakening the balance sheet, limiting capacity to absorb prolonged development delays.
ValiRx plc News
VAL FAQ
What was ValiRx PLC’s price range in the past 12 months?
ValiRx PLC lowest share price was 0.12 p and its highest was 0.53 p in the past 12 months.
What is ValiRx PLC’s market cap?
ValiRx PLC’s market cap is £1.85M.
When is ValiRx PLC’s upcoming earnings report date?
ValiRx PLC’s upcoming earnings report date is Jun 09, 2027 which is in 227 days.
How were ValiRx PLC’s earnings last quarter?
ValiRx PLC released its earnings results on Sep 15, 2026. The company reported -0.001 p earnings per share for the quarter.
Is ValiRx PLC overvalued?
According to Wall Street analysts ValiRx PLC’s price is currently Overvalued.
Does ValiRx PLC pay dividends?
ValiRx PLC does not currently pay dividends.
What is ValiRx PLC’s EPS estimate?
ValiRx PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ValiRx PLC have?
ValiRx PLC has 1,320,301,000 shares outstanding.
What happened to ValiRx PLC’s price movement after its last earnings report?
ValiRx PLC reported an EPS of -0.001 p in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ValiRx PLC?
Currently, no hedge funds are holding shares in GB:VAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ValiRx PLC
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat prostate cancer and other hormone-dependent solid tumors, including breast and ovarian cancer. Another key candidate, VAL401, a reimagined version of the antipsychotic drug risperidone, has successfully completed Phase II clinical trials for addressing non-small cell lung cancer. The company's pipeline also features VAL301, a peptide currently in pre-clinical development for treating endometriosis in women. Additionally, BC201, a compound combining the peptide ingredient from VAL201/VAL301 with complementary active components, is being developed to alleviate severe symptoms of COVID-19. ValiRx plc was established in 2000 and is headquartered in Hatfield, United Kingdom.
Technical Analysis
Evgen Pharma
―
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―